Genprex (NASDAQ:GNPX – Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 36,884 shares, a decrease of 95.8% from the July 15th total of 884,893 shares. Based on an average daily volume of 50,133 shares, the short-interest ratio is currently 0.7 days. Currently, 7.3% of the company’s stock are short sold.
Genprex Stock Up 5.1%
NASDAQ:GNPX traded up $0.23 during trading hours on Wednesday, reaching $4.70. 43,002 shares of the stock were exchanged, compared to its average volume of 61,095. The stock has a market capitalization of $2.37 million, a P/E ratio of -0.02 and a beta of -0.88. The firm has a 50 day simple moving average of $10.11 and a 200-day simple moving average of $26.23. Genprex has a 52 week low of $4.00 and a 52 week high of $1,210.00.
Genprex (NASDAQ:GNPX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($14.08) earnings per share (EPS) for the quarter.
Analysts Set New Price Targets
Get Our Latest Analysis on Genprex
Institutional Trading of Genprex
A number of institutional investors and hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP grew its position in shares of Genprex by 11.7% during the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the last quarter. Manchester Financial Inc. acquired a new stake in Genprex during the first quarter worth about $36,000. Finally, Mayflower Financial Advisors LLC bought a new position in Genprex in the first quarter worth about $36,000. 14.05% of the stock is owned by institutional investors and hedge funds.
About Genprex
Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.
In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.
See Also
- Five stocks we like better than Genprex
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
- Visa’s AI Opportunity Is Hiding in Every Transaction
- On Holding’s Price Stumble May Be an Opening for a Company Built to Run
- TSMC’s 44.7% Sales Surge Signals the AI Boom Is Still Alive
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
